| abstract |
The present invention relates to a novel T cell receptor (TCR), in particular at least one complementarity determining region (CDR) of the TCR; a T lymphocyte expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or an immunogenic or bispecific agent or a vaccine comprising said TCR, said lymphocyte, said clone or said vector; the use of said TCR or said lymphocyte or said clone or said vector or said pharmaceutical composition or said immunogenic or bispecific agent or vaccine for treating cancer; and a method of treating cancer using said TCR, said lymphocyte, said clone, said vector, said pharmaceutical composition or said immunogenic or bispecific agent or vaccine comprising said TCR. |